Drug details

Rezlidhia (olutasidenib capsules)

type of IDH1 Inhibitors

Rezlidhia (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible DH1 mutation as detected by an FDA-approved test.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• loss of appetite,
• tiredness,
• weakness, and
• stomach pain (upper right side),
• dark colored urine,
• yellowing of your skin or eyes (jaundice)

The following drugs are related to Rezlidhia, either as a replacement or used together:

• Cytarabine (cytarabine)
• Sprycel (dasatinib)
• Dxevo (dexamethasone tablets)
• Idamycin (idarubicin)
• Kenalog-40 Injection (triamcinolone acetonide injectable suspension)
• Prednisone (prednisone tablets, usp)